FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1963967933> ?p ?o ?g. }

• W1963967933 endingPage "196" @default.
• W1963967933 startingPage "189" @default.
• W1963967933 abstract "Objective To describe the rate of development of in vitro HIV resistance to zidovudine (ZDV) and its prognostic implications within the Multicentre Canadian AZT Trial (MCAT). Methods HIV-infected subjects in Centers for Disease Control (CDC) stages IIB, III and IVC-2 with CD4 cell counts > 270 x 106/I were treated with ZDV as part of a dose-range study. Participating volunteers underwent prospective clinical and laboratory evaluations at regular intervals. Viral cultures and sensitivity testing were performed every 12 weeks in a predefined subset of 50 volunteers. An isolate was designated ZDV-resistant if it had a median inhibitory concentration (IC50) for ZDV at least 50-fold higher than that of virus isolated from the same subject before initiation of antiviral chemotherapy. The relationship between resistance and subsequent disease progression was studied using the Mantel and Byar method, for which, at each instance of disease progression, 2 x 2 tables classifying progression versus resistance status were constructed. The observed number of progressions was compared with that expected under the null hypothesis using Mantel-Haenszel methods adjusted for baseline CD4: CD8 ratio. Results The Kaplan-Meier estimate for the cumulative development of in vitro resistance was 64% [95% confidence interval (CI), 41–78] at 180 weeks. Baseline CD4: CD8 ratio was negatively associated (P = 0.10) with the subsequent development of resistance (proportional hazard, 0.44; 95% CI, 0.17–1.10). After adjusting for baseline CD4:CD8 ratio, the numbers of observed and expected progressions following the development of resistance were 15 and 7.6, respectively (P = 0.008). A similar relative risk of progression between resistant and non-resistant states was found in the two CD4:CD8 strata; observed and expected progressions were 4 and 2.3 and 11 and 5.2 in the high and low CD4: CD8 strata, respectively. Conclusions In vitro resistance to ZDV developed in 64% of subjects after 180 weeks of ZDV therapy. Lower CD4: CD8 ratio at baseline was associated with faster development of resistance. In addition, the development of resistance was found to be a marker of subsequent disease progression. This association persisted after adjustment for baseline CD4: CD8 ratio. Whether in vitro resistance to ZDV is merely a surrogate marker or a determinant of disease progression remains to be established." @default.
• W1963967933 created "2016-06-24" @default.
• W1963967933 creator A5006756888 @default.
• W1963967933 creator A5017695842 @default.
• W1963967933 creator A5035215851 @default.
• W1963967933 creator A5045151498 @default.
• W1963967933 creator A5046341729 @default.
• W1963967933 creator A5047852129 @default.
• W1963967933 creator A5049648167 @default.
• W1963967933 creator A5052920122 @default.
• W1963967933 creator A5074441717 @default.
• W1963967933 creator A5081889363 @default.
• W1963967933 date "1993-02-01" @default.
• W1963967933 modified "2023-10-07" @default.
• W1963967933 title "Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial" @default.
• W1963967933 doi "https://doi.org/10.1097/00002030-199302000-00006" @default.
• W1963967933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8466681" @default.
• W1963967933 hasPublicationYear "1993" @default.
• W1963967933 type Work @default.
• W1963967933 sameAs 1963967933 @default.
• W1963967933 citedByCount "64" @default.
• W1963967933 crossrefType "journal-article" @default.
• W1963967933 hasAuthorship W1963967933A5006756888 @default.
• W1963967933 hasAuthorship W1963967933A5017695842 @default.
• W1963967933 hasAuthorship W1963967933A5035215851 @default.
• W1963967933 hasAuthorship W1963967933A5045151498 @default.
• W1963967933 hasAuthorship W1963967933A5046341729 @default.
• W1963967933 hasAuthorship W1963967933A5047852129 @default.
• W1963967933 hasAuthorship W1963967933A5049648167 @default.
• W1963967933 hasAuthorship W1963967933A5052920122 @default.
• W1963967933 hasAuthorship W1963967933A5074441717 @default.
• W1963967933 hasAuthorship W1963967933A5081889363 @default.
• W1963967933 hasConcept C114851261 @default.
• W1963967933 hasConcept C126322002 @default.
• W1963967933 hasConcept C203014093 @default.
• W1963967933 hasConcept C207103383 @default.
• W1963967933 hasConcept C2776452011 @default.
• W1963967933 hasConcept C2780216070 @default.
• W1963967933 hasConcept C2780727368 @default.
• W1963967933 hasConcept C3013748606 @default.
• W1963967933 hasConcept C44249647 @default.
• W1963967933 hasConcept C71924100 @default.
• W1963967933 hasConcept C86803240 @default.
• W1963967933 hasConcept C89423630 @default.
• W1963967933 hasConcept C90924648 @default.
• W1963967933 hasConceptScore W1963967933C114851261 @default.
• W1963967933 hasConceptScore W1963967933C126322002 @default.
• W1963967933 hasConceptScore W1963967933C203014093 @default.
• W1963967933 hasConceptScore W1963967933C207103383 @default.
• W1963967933 hasConceptScore W1963967933C2776452011 @default.
• W1963967933 hasConceptScore W1963967933C2780216070 @default.
• W1963967933 hasConceptScore W1963967933C2780727368 @default.
• W1963967933 hasConceptScore W1963967933C3013748606 @default.
• W1963967933 hasConceptScore W1963967933C44249647 @default.
• W1963967933 hasConceptScore W1963967933C71924100 @default.
• W1963967933 hasConceptScore W1963967933C86803240 @default.
• W1963967933 hasConceptScore W1963967933C89423630 @default.
• W1963967933 hasConceptScore W1963967933C90924648 @default.
• W1963967933 hasIssue "2" @default.
• W1963967933 hasLocation W19639679331 @default.
• W1963967933 hasLocation W19639679332 @default.
• W1963967933 hasOpenAccess W1963967933 @default.
• W1963967933 hasPrimaryLocation W19639679331 @default.
• W1963967933 hasRelatedWork W127593504 @default.
• W1963967933 hasRelatedWork W1831739951 @default.
• W1963967933 hasRelatedWork W1971108536 @default.
• W1963967933 hasRelatedWork W1975455892 @default.
• W1963967933 hasRelatedWork W2048005133 @default.
• W1963967933 hasRelatedWork W2109259850 @default.
• W1963967933 hasRelatedWork W2143414727 @default.
• W1963967933 hasRelatedWork W2418187424 @default.
• W1963967933 hasRelatedWork W76273905 @default.
• W1963967933 hasRelatedWork W2488499266 @default.
• W1963967933 hasVolume "7" @default.
• W1963967933 isParatext "false" @default.
• W1963967933 isRetracted "false" @default.
• W1963967933 magId "1963967933" @default.
• W1963967933 workType "article" @default.